Kenji Tago
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kenji Tago has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Megumi Funakoshi-Tago
Division of Hygienic Chemistry, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan
18 shared publications - Junji Yamauchi
Laboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan
7 shared publications Satoshi Ohta
Division of Structural Biochemistry, Department of Biochemistry, School of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, 329-0498 Tochigi, Japan
6 shared publicationsHiroomi Tamura
Division of Hygienic Chemistry, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan
5 shared publicationsJitsuhiro Matsugi
Department of Biochemistry Jichi Medical University Tochigi Japan
5 shared publicationsXin Lin
Division of Hygienic Chemistry, Faculty of Pharmacy, Keio University, Tokyo, Japan
5 shared publications
Latest Publications
- Open Access
- 14 June 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 185, 116969
Methotrexate inhibits the TEL-JAK2–STAT pathway through a folate metabolism-dependent mechanism in Ba/F3 cells
- 14 June 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 185, 116969
Open AccessMethotrexate inhibits the TEL-JAK2–STAT pathway through a folate metabolism-dependent mechanism in Ba/F3 cells
- Open Access
- 25 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
A critical role for STAT3 Thr714 phosphorylation in NPM-ALK-driven tumorigenesis
The oncogenic fusion protein NPM-ALK drives anaplastic large cell lymphoma (ALCL) by activating the transcription factor STAT3. While STAT3 phosphorylation at Y705 and S727 is well characterized, the present study defines a mechanistic role for phosphorylation at T714 in supporting full STAT3 functionality. In NPM-ALK–positive ALCL cells, STAT3 is phosphorylated at Y705, S727, and T714, and this is suppressed by ALK inhibition. Enforced NPM-ALK expression in Ba/F3 cells induces phosphorylation at all three sites in a kinase-dependent manner. To investigate the role of T714, wild-type STAT3 or a T714A mutant was reconstituted into STAT3-knockdown Ba/F3 cells expressing NPM-ALK. Wild-type STAT3 underwent Y705 and S727 phosphorylation and nuclear translocation, whereas the T714A mutant was phosphorylated at S727 only and failed to translocate. The reduced expression of STAT3 target genes (Cyclin D1, Pim1, Pim2, and Socs3) with STAT3 knockdown was restored by wild-type STAT3, but not by the T714A mutant. In vivo, STAT3 knockdown suppressed tumor formation and hepatosplenomegaly in mice inoculated with Ba/F3 cells expressing NPM-ALK, and these phenotypes were rescued by wild-type STAT3, but not by the T714A mutant. These findings indicate that STAT3 phosphorylation at T714 is required for subsequent Y705 phosphorylation, nuclear translocation, and transcriptional activation specifically within the context of NPM-ALK–mediated signaling.
- 25 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessA critical role for STAT3 Thr714 phosphorylation in NPM-ALK-driven tumorigenesis
The oncogenic fusion protein NPM-ALK drives anaplastic large cell lymphoma (ALCL) by activating the transcription factor STAT3. While STAT3 phosphorylation at Y705 and S727 is well characterized, the present study defines a mechanistic role for phosphorylation at T714 in supporting full STAT3 functionality. In NPM-ALK–positive ALCL cells, STAT3 is phosphorylated at Y705, S727, and T714, and this is suppressed by ALK inhibition. Enforced NPM-ALK expression in Ba/F3 cells induces phosphorylation at all three sites in a kinase-dependent manner. To investigate the role of T714, wild-type STAT3 or a T714A mutant was reconstituted into STAT3-knockdown Ba/F3 cells expressing NPM-ALK. Wild-type STAT3 underwent Y705 and S727 phosphorylation and nuclear translocation, whereas the T714A mutant was phosphorylated at S727 only and failed to translocate. The reduced expression of STAT3 target genes (Cyclin D1, Pim1, Pim2, and Socs3) with STAT3 knockdown was restored by wild-type STAT3, but not by the T714A mutant. In vivo, STAT3 knockdown suppressed tumor formation and hepatosplenomegaly in mice inoculated with Ba/F3 cells expressing NPM-ALK, and these phenotypes were rescued by wild-type STAT3, but not by the T714A mutant. These findings indicate that STAT3 phosphorylation at T714 is required for subsequent Y705 phosphorylation, nuclear translocation, and transcriptional activation specifically within the context of NPM-ALK–mediated signaling.
- Open Access
- 31 January 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 173, 116284
Targeting DDX5 using FL118 suppresses mTOR signaling and tumorigenicity in JAK2V617F-driven myeloproliferative neoplasms
- 31 January 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 173, 116284
Open AccessTargeting DDX5 using FL118 suppresses mTOR signaling and tumorigenicity in JAK2V617F-driven myeloproliferative neoplasms
- Open Access
- 21 November 2025
- Published by Elsevier in Cellular Signalling
- Vol. 138, 112248
DDX5 is required for JAK2V617F-induced cell proliferation and tumorigenesis independent of its RNA helicase activity
- 21 November 2025
- Published by Elsevier in Cellular Signalling
- Vol. 138, 112248
Open AccessDDX5 is required for JAK2V617F-induced cell proliferation and tumorigenesis independent of its RNA helicase activity
- Open Access
- 25 October 2025
- Published by Elsevier in Cellular Signalling
- Vol. 137, 112194
KMN003 activates Nrf2 via disruption of the Keap1-Nrf2 interaction and p38-dependent transcriptional regulation
- 25 October 2025
- Published by Elsevier in Cellular Signalling
- Vol. 137, 112194
Open AccessKMN003 activates Nrf2 via disruption of the Keap1-Nrf2 interaction and p38-dependent transcriptional regulation
- Open Access
- 25 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10388
STK38 Kinase Promotes Cell Migration Induced by Oncogenic Ras via MerTK Activation
Ras gene mutations are frequently observed in many types of cancers. However, there are currently no effective anticancer drugs against Ras-induced cancers. Therefore, identifying the downstream effectors of the Ras signaling pathway can facilitate the development of promising novel therapeutic approaches. We previously showed that oncogenic Ras induces the expression of the receptor tyrosine kinase c-Mer proto-oncogene tyrosine kinase (MerTK) in an interleukin-1 family member NF-HEV/IL-33-dependent manner and that IL-33 and MerTK contribute to oncogenic Ras-induced cell migration. In the present study, we purified the MerTK complex from NIH-3T3 cells transformed by the expression of oncogenic Ras, H-Ras (G12V). Mass spectrometric analysis identified STK38 (also known as NDR1) as a candidate binding partner for MerTK. STK38 is a serine/threonine protein kinase that plays diverse roles in normal and cancerous cells. In addition to MerTK knockdown, STK38 knockdown effectively attenuated the H-Ras (G12V)-induced migration of NIH-3T3 cells. STK38 kinase activity is required for oncogenic Ras-induced cell migration and MerTK tyrosine phosphorylation. Furthermore, MerTK or STK38 knockdown attenuated the activation of Rac1 and Cdc42. Taken together, these results revealed a novel role for STK38 in oncogenic Ras-induced enhanced cell migration, which may be useful for developing novel therapeutic strategies targeting Ras-mutated cells.
- 25 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10388
Open AccessSTK38 Kinase Promotes Cell Migration Induced by Oncogenic Ras via MerTK Activation
Ras gene mutations are frequently observed in many types of cancers. However, there are currently no effective anticancer drugs against Ras-induced cancers. Therefore, identifying the downstream effectors of the Ras signaling pathway can facilitate the development of promising novel therapeutic approaches. We previously showed that oncogenic Ras induces the expression of the receptor tyrosine kinase c-Mer proto-oncogene tyrosine kinase (MerTK) in an interleukin-1 family member NF-HEV/IL-33-dependent manner and that IL-33 and MerTK contribute to oncogenic Ras-induced cell migration. In the present study, we purified the MerTK complex from NIH-3T3 cells transformed by the expression of oncogenic Ras, H-Ras (G12V). Mass spectrometric analysis identified STK38 (also known as NDR1) as a candidate binding partner for MerTK. STK38 is a serine/threonine protein kinase that plays diverse roles in normal and cancerous cells. In addition to MerTK knockdown, STK38 knockdown effectively attenuated the H-Ras (G12V)-induced migration of NIH-3T3 cells. STK38 kinase activity is required for oncogenic Ras-induced cell migration and MerTK tyrosine phosphorylation. Furthermore, MerTK or STK38 knockdown attenuated the activation of Rac1 and Cdc42. Taken together, these results revealed a novel role for STK38 in oncogenic Ras-induced enhanced cell migration, which may be useful for developing novel therapeutic strategies targeting Ras-mutated cells.
- Open Access
- 14 September 2025
- Published by Elsevier in Cellular Signalling
- Vol. 136, 112128
The critical role of the phosphorylation of STAT3 at Y705 in ALCL-associated NPM-ALK-induced transforming activity
- 14 September 2025
- Published by Elsevier in Cellular Signalling
- Vol. 136, 112128
Open AccessThe critical role of the phosphorylation of STAT3 at Y705 in ALCL-associated NPM-ALK-induced transforming activity
- Open Access
- 26 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (7) , 3693
FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5
Chronic myeloid leukemia (CML) is induced by the expression of the fused tyrosine kinase BCR-ABL, which is caused by a chromosomal translocation. BCR-ABL inhibitors have been used to treat CML; however, the acquisition of resistance by CML cells during treatment is a serious issue. We herein demonstrated that BCR-ABL induced the expression of the RNA helicase DDX5 in K562 cells derived from CML patients in a manner that was dependent on its kinase activity, which resulted in cell proliferation and survival. The knockout of DDX5 decreased the expression of BIRC5 (survivin) and activated caspase 3, leading to apoptosis in K562 cells. Similar results were obtained in cells treated with FL118, an inhibitor of DDX5 and a derivative compound of camptothecin (CPT). Furthermore, FL118 potently induced apoptosis not only in Ba/F3 cells expressing BCR-ABL, but also in those expressing the BCR-ABL T315I mutant, which is resistant to BCR-ABL inhibitors. Collectively, these results revealed that DDX5 is a critical therapeutic target in CML and that FL118 is an effective candidate compound for the treatment of BCR-ABL inhibitor-resistant CML.
- 26 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (7) , 3693
Open AccessFL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5
Chronic myeloid leukemia (CML) is induced by the expression of the fused tyrosine kinase BCR-ABL, which is caused by a chromosomal translocation. BCR-ABL inhibitors have been used to treat CML; however, the acquisition of resistance by CML cells during treatment is a serious issue. We herein demonstrated that BCR-ABL induced the expression of the RNA helicase DDX5 in K562 cells derived from CML patients in a manner that was dependent on its kinase activity, which resulted in cell proliferation and survival. The knockout of DDX5 decreased the expression of BIRC5 (survivin) and activated caspase 3, leading to apoptosis in K562 cells. Similar results were obtained in cells treated with FL118, an inhibitor of DDX5 and a derivative compound of camptothecin (CPT). Furthermore, FL118 potently induced apoptosis not only in Ba/F3 cells expressing BCR-ABL, but also in those expressing the BCR-ABL T315I mutant, which is resistant to BCR-ABL inhibitors. Collectively, these results revealed that DDX5 is a critical therapeutic target in CML and that FL118 is an effective candidate compound for the treatment of BCR-ABL inhibitor-resistant CML.
- Open Access
- 25 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (1) , 316
Suppression of Neuroinflammation by Coffee Component Pyrocatechol via Inhibition of NF-κB in Microglia
According to numerous studies, it has been epidemiologically suggested that habitual coffee intake seems to prevent the onset of neurodegenerative diseases. In this study, we hypothesized that coffee consumption suppresses neuroinflammation, which is closely related to the development of neurodegenerative diseases. Using microglial BV-2 cells, we first found that the inflammatory responses induced by lipopolysaccharide (LPS) stimulation was diminished by both coffee and decaffeinated coffee through the inhibition of an inflammation-related transcription factor, nuclear factor-κB (NF-κB). Pyrocatechol, a component of roasted coffee produced by the thermal decomposition of chlorogenic acid, also exhibited anti-inflammatory activity by inhibiting the LPS-induced activation of NF-κB. Finally, in an inflammation model using mice injected with LPS into the cerebrum, we observed that intake of pyrocatechol as well as coffee decoctions drastically suppressed the accumulation of microglia and the expression of interleukin-6 (IL-6), tumor necrosis factor α (TNFα), CCL2, and CXCL1 in the inflammatory brain. These observations strongly encourage us to hypothesize that the anti-inflammatory activity of pyrocatechol as well as coffee decoction would be useful for the suppression of neurodegeneration and the prevention of the onsets of Alzheimer’s (AD) and Perkinson’s diseases (PD).
- 25 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (1) , 316
Open AccessSuppression of Neuroinflammation by Coffee Component Pyrocatechol via Inhibition of NF-κB in Microglia
According to numerous studies, it has been epidemiologically suggested that habitual coffee intake seems to prevent the onset of neurodegenerative diseases. In this study, we hypothesized that coffee consumption suppresses neuroinflammation, which is closely related to the development of neurodegenerative diseases. Using microglial BV-2 cells, we first found that the inflammatory responses induced by lipopolysaccharide (LPS) stimulation was diminished by both coffee and decaffeinated coffee through the inhibition of an inflammation-related transcription factor, nuclear factor-κB (NF-κB). Pyrocatechol, a component of roasted coffee produced by the thermal decomposition of chlorogenic acid, also exhibited anti-inflammatory activity by inhibiting the LPS-induced activation of NF-κB. Finally, in an inflammation model using mice injected with LPS into the cerebrum, we observed that intake of pyrocatechol as well as coffee decoctions drastically suppressed the accumulation of microglia and the expression of interleukin-6 (IL-6), tumor necrosis factor α (TNFα), CCL2, and CXCL1 in the inflammatory brain. These observations strongly encourage us to hypothesize that the anti-inflammatory activity of pyrocatechol as well as coffee decoction would be useful for the suppression of neurodegeneration and the prevention of the onsets of Alzheimer’s (AD) and Perkinson’s diseases (PD).
- 22 November 2023
- Published by Elsevier in Cellular Signalling
- Vol. 114, 110985
The acetylation of STAT3 at K685 attenuates NPM-ALK-induced tumorigenesis
- 22 November 2023
- Published by Elsevier in Cellular Signalling
- Vol. 114, 110985
The acetylation of STAT3 at K685 attenuates NPM-ALK-induced tumorigenesis